VikkiWithNoKidney's peptide therapy claims need context

What did @vikki.balinag actually say?

Vikki shared a personal medical history spanning from a 1998 diagnosis of acute glomerulonephritis through a 2002 kidney biopsy that confirmed IgA nephropathy and CKD Stage 2. She describes being prescribed imidapril, an ACE inhibitor she says offers "kidney protection property," and fish oil, which she claims has "anti-inflammatory property that could lower down the IgA levels." She also mentions exercise and dietary modification as part of her management. The video is a personal story, not a protocol recommendation, but the medical claims embedded in it are specific enough to warrant scrutiny. To her credit, she frames this as her own experience and encourages viewers to ask their doctors, not to copy her regimen.

Does the science back this up?

On ACE inhibitors for IgA nephropathy, the evidence is solid. The use of fish oil is more contested than she implies, but not without support.

ACE inhibitors and ARBs are considered standard first-line therapy for IgA nephropathy with proteinuria. The 2021 KDIGO Clinical Practice Guidelines explicitly recommend renin-angiotensin system blockade to reduce proteinuria and slow GFR decline. Imidapril is used in several Asian countries and shares the same mechanism as more commonly studied agents like ramipril and enalapril. The REIN trial (Ruggenenti et al., 1997, Lancet) and subsequent meta-analyses confirm ACE inhibitors reduce proteinuria and delay progression to end-stage kidney disease in chronic glomerular diseases.

Fish oil is trickier. The original Mayo Clinic trials (Donadio et al., 1994, New England Journal of Medicine) showed a modest benefit for high-risk IgA nephropathy patients, but a 2012 Cochrane review (Dillon, 2012) found insufficient evidence to make broad recommendations. The KDIGO 2021 guidelines stopped short of recommending fish oil as standard therapy, noting inconsistent trial results. Vikki's claim that fish oil "lowers IgA levels" specifically is not well-supported by current evidence. It may reduce systemic inflammation, but its effect on mesangial IgA deposits is not established.

What did they get wrong (or right)?

She got the ACE inhibitor rationale right. She got fish oil partially right but overstated the mechanism.

Saying imidapril was given to "protect the cells of the kidney" is a reasonable lay description of how RAS blockade reduces intraglomerular pressure and proteinuria. That is accurate and consistent with nephrology practice.

The claim that fish oil works because of "anti-inflammatory property that could lower down the IgA levels" is where she oversimplifies. Omega-3s reduce systemic inflammatory markers like IL-6 and TNF-alpha, but there is no strong human trial showing they meaningfully reduce circulating or mesangially-deposited IgA. The mechanism she describes is plausible in theory but not confirmed in the way she presents it.

She also correctly identifies that IgA nephropathy has no single cure and that her management goal was to "delay the progression to CKD Stage 5." This is exactly what the nephrology literature supports. No disease-modifying therapy existed until sparsentan and targeted-release budesonide (Nefecon/Tarpeyo) received conditional FDA approval in 2023, both after her initial diagnosis period.

What should you actually know?

IgA nephropathy is the most common primary glomerulonephritis worldwide, and the management landscape shifted significantly in 2023.

• Around 20-40% of IgA nephropathy patients progress to kidney failure within 20 years (Wyatt and Julian, 2013, New England Journal of Medicine).
• ACE inhibitors and ARBs remain first-line for patients with proteinuria above 0.5-1g per day, per KDIGO 2021 guidelines.
• The SPARTAN trial (Heerspink et al., 2023, NEJM) showed sparsentan reduced proteinuria significantly compared to irbesartan at 36 weeks, representing the first targeted approval for IgA nephropathy in the US.
• Targeted-release budesonide (Tarpeyo) received full FDA approval in 2023 based on the NefIgArd trial, showing sustained GFR preservation. This is the kind of disease-modifying approach that was unavailable to Vikki in 2002.
• Fish oil is not currently a standard-of-care recommendation per KDIGO 2021, though some nephrologists still use it in low-risk patients.
• Anyone with IgA nephropathy should be under active nephrology care, not managing progression based on social media, including this video.